Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

129.46 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

BPMC stock results show that Blueprint Medicines beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday ↗

May 02, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 01, 2024

Via Benzinga

The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts ↗

April 26, 2024

Via Benzinga

Decoding 6 Analyst Evaluations For Blueprint Medicines ↗

April 10, 2024

Via Benzinga

(BPMC) - Analyzing Blueprint Medicines's Short Interest ↗

February 20, 2024

Via Benzinga

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Blueprint Medicines Corp. (NASDAQ: BPMC) Climbs to New 52-Week High

February 16, 2024

Via Investor Brand Network

Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday ↗

February 15, 2024

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.

Via Benzinga

Topics Stocks

Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing. ↗

February 15, 2024

The company reported better-than-expected sales of its rare-disease drug, but there's one drawback in its report.

Via Investor's Business Daily

Blueprint Medicines's Earnings Outlook ↗

February 14, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Blueprint Medicines ↗

February 13, 2024

Via Benzinga

Peeling Back The Layers: Exploring Blueprint Medicines Through Analyst Insights ↗

January 09, 2024

Via Benzinga

The Latest Analyst Ratings for Blueprint Medicines ↗

December 11, 2023

Via Benzinga

Raymond James Maintains Strong Buy Rating for Blueprint Medicines: Here's What You Need To Know ↗

December 22, 2023

Via Benzinga

Chart Of The Day: Does Blueprint Medicines Have A Blueprint For Success? ↗

December 13, 2023

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.

Via Talk Markets

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

December 11, 2023

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the...

Via Benzinga

Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To Know ↗

October 27, 2023

Via Benzinga

Blueprint Medicines's Earnings: A Preview ↗

October 25, 2023

Via Benzinga

Analyst Ratings for Blueprint Medicines ↗

August 21, 2023

Via Benzinga

What 15 Analyst Ratings Have To Say About Blueprint Medicines ↗

August 02, 2023

Via Benzinga

Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To Know ↗

October 27, 2023

Via Benzinga

Why Blueprint Medicines Stock Soared Today ↗

October 26, 2023

The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 26, 2023

Via Benzinga

Blueprint Medicines Corp. (NASDAQ: BPMC) Leading the Way in Thursday Trading Based on Percentage Gain

October 26, 2023

Via Investor Brand Network

Unpacking Blueprint Medicines' Ayvakit's Bright Future: Insights From Latest Physician Survey On Sales Predictions ↗

August 21, 2023

Needham slightly increased the price target for Blueprint Medicines Corp (NASDAQ: BPMC) from $65 to $66

Via Benzinga

Why Shares of Blueprint Medicines Are Falling Wednesday ↗

August 02, 2023

The company had generally improved earnings.

Via The Motley Fool

A Preview Of Blueprint Medicines's Earnings ↗

August 01, 2023

Via Benzinga

Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

October 26, 2023

Gainers

Via Benzinga

IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday ↗

October 26, 2023

U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session.

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.